Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Equity Income: 2020-2025

Historic Equity Income for Pharming Group N.V (PHAR) over the last 4 years, with Jun 2025 value amounting to $8,000.

  • Pharming Group N.V's Equity Income rose 100.96% to $8,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.8 million, marking a year-over-year decrease of 51.82%. This contributed to the annual value of -$1.8 million for FY2024, which is 509.00% down from last year.
  • Latest data reveals that Pharming Group N.V reported Equity Income of $8,000 as of Q2 2025, which was up 101.65% from -$484,000 recorded in Q4 2024.
  • Pharming Group N.V's Equity Income's 5-year high stood at $991,000 during Q2 2022, with a 5-year trough of -$1.2 million in Q3 2022.
  • Its 3-year average for Equity Income is -$178,111, with a median of -$442,000 in 2024.
  • Examining YoY changes over the last 5 years, Pharming Group N.V's Equity Income showed a top increase of 637.80% in 2022 and a maximum decrease of 1,083.74% in 2022.
  • Over the past 5 years, Pharming Group N.V's Equity Income (Quarterly) stood at -$82,000 in 2021, then surged by 637.80% to $441,000 in 2022, then soared by 50.79% to $665,000 in 2023, then tumbled by 172.78% to -$484,000 in 2024, then spiked by 100.96% to $8,000 in 2025.
  • Its last three reported values are $8,000 in Q2 2025, -$484,000 for Q4 2024, and -$442,000 during Q3 2024.